In:
Tumori Journal, SAGE Publications, Vol. 87, No. 6 ( 2001-11), p. 391-393
Kurzfassung:
The treatment of inoperable malignant pleural mesothelioma is a challenge for the oncologist. Available chemotherapy regimens achieve poor results, therefore new agents or combinations are needed. In a phase I study, the combination of oxaliplatin and raltitrexed was shown to be active against malignant pleural mesothelioma. We herein report the results of a pilot study about the treatment of this disease. Methods From April 1999 to June 2000, we enrolled 11 chemotherapy-naïve patients with inoperable malignant pleural mesothelioma suitable to receive the following combination chemotherapy: raltitrexed, 3 mg/m 2 iv, and oxaliplatin, 130 mg/m 2 , as a 2-hr infusion every 3 weeks. Results Four partial responses, 1 regression of disease (objective response rate, 45%; 95% Cl, 15.6-74.4%), 4 stable diseases and 2 progressions of disease were observed. An improvement in disease-related symptoms was recorded in all responders and in 2 patients with stable disease. Toxicity was mild, with no toxic-related death and only 1 episode of grade 4 neurotoxicity. Conclusions We consider the combination promising and worthy of further studies.
Materialart:
Online-Ressource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/030089160108700607
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2001
ZDB Id:
280962-X
ZDB Id:
2267832-3
